AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7418714 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg methotrexate bolus intravenous injection
Number of subjects: 6
Study 31674250 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal femoral replacement (DFR)
Number of subjects: 36
Study 31674250 — intervention group
Group type: COMPARATOR
Intervention: Internal fracture fixation
Number of subjects: 36
Study 27067259 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 28
Study 27067259 — intervention group
Group type: COMPARATOR
Intervention: Sham TES (Control)
Number of subjects: 28
Study 27123806 — intervention group
Group type: EXPERIMENTAL
Intervention: Social worker contact
Number of subjects: 267
Study 27123806 — intervention group
Group type: COMPARATOR
Intervention: Other incentive strategies
Number of subjects: 267
Study 24512733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C 320 mg/kg
Number of subjects: 36
Study 24512733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C 480 mg/kg
Number of subjects: 36
Study 24512733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22489991 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight lightwand
Number of subjects: 300
Study 22489991 — intervention group
Group type: COMPARATOR
Intervention: Bonfils fibrescope
Number of subjects: 300
Study 20668047 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (mean maximum daily dose, 1.4 ± 0.12 mg/d)
Number of subjects: 21
Study 20668047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20668047 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 21
Study 17202435 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA-supplemented 20% lipid emulsion (Lipoplus)
Number of subjects: 40
Study 17202435 — intervention group
Group type: COMPARATOR
Intervention: Standard 20% fat emulsion (Lipofundin MCT/LCT)
Number of subjects: 40
Study 16327500 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection (UC)
Number of subjects: 146
Study 16327500 — intervention group
Group type: COMPARATOR
Intervention: Standard electrosurgery (ES)
Number of subjects: 146
Study 11931780 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with fomivirsen (165 microg administered intravitreously, injected weekly for three doses as induction therapy, followed by every other week as maintenance therapy)
Number of subjects: 28
Study 11931780 — intervention group
Group type: COMPARATOR
Intervention: Deferral of treatment until CMV retinitis lesions progressed
Number of subjects: 28
Study 9803696 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT + SW with monetary incentives (I) for completing SW
Number of subjects: 193
Study 9803696 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT + SW with personal trainers (PT)
Number of subjects: 193
Study 9803696 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT + SW + PT + I
Number of subjects: 193
Study 9803696 — intervention group
Group type: COMPARATOR
Intervention: SBT
Number of subjects: 193
Study 7701451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 5 mg
Number of subjects: 11
Study 7701451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous gamma-globulin (0.5 g/kg/wk)
Number of subjects: 80
Study 2651367 — intervention group
Group type: COMPARATOR
Intervention: Control group (17 infants with birthweight ≤ 1500 g and 20 infants with birthweight 1501-2000 g)
Number of subjects: 80
Study 2651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants under intensive care receiving intravenous gamma-globulin
Number of subjects: 80
Study 2651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with sepsis
Number of subjects: 80
Study 2651367 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dose serum IgG levels
Number of subjects: 80
Study 31454351 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard RUTF dose throughout treatment
Number of subjects: 801
Study 31454351 — intervention group
Group type: COMPARATOR
Intervention: Reduced RUTF dose after two weeks
Number of subjects: 801
Study 31454351 — intervention group
Group type: COMPARATOR
Intervention: Reduced RUTF dose after two weeks (children under 12 months)
Number of subjects: 801
Study 29092882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowpea
Number of subjects: 355
Study 29092882 — intervention group
Group type: EXPERIMENTAL
Intervention: Common bean
Number of subjects: 355
Study 29092882 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 355
Study 25672923 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense immunosuppression followed by autologous hematopoietic stem cell transplantation (AHSCT)
Number of subjects: 21
Study 25672923 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone (MTX) 20 mg every month for 6 months
Number of subjects: 21
Study 24392700 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential/ruminative self‐focus conditions
Number of subjects: 60
Study 24392700 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination and health anxiety
Number of subjects: 60
Study 23030430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 212
Study 23030430 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 212
Study 19812448 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 2594
Study 19812448 — intervention group
Group type: COMPARATOR
Intervention: HIV treatment without concomitant statin use (Control)
Number of subjects: 2594
Study 17483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/day)
Number of subjects: 59
Study 15231551 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 191
Study 15231551 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 191
Study 15231551 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 191
Study 11603388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 micrograms/kg body weight)
Number of subjects: 200
Study 11603388 — intervention group
Group type: COMPARATOR
Intervention: 1% topical lindane lotion
Number of subjects: 200
Study 9587747 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 60
Study 9587747 — intervention group
Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 60
Study 8027926 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccoadhesive film
Number of subjects: 6
Study 8027926 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccoadhesive tablet
Number of subjects: 6
Study 8027926 — intervention group
Group type: COMPARATOR
Intervention: Sublingual capsule
Number of subjects: 6
Study 2644962 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine preparation (0.5 g applied for 30 min)
Number of subjects: 0
Study 2644962 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic Mixture of Local Anaesthetics (EMLA) (2.5 g applied for 60 min under an occlusive dressing)
Number of subjects: 0
Study 2644962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2644962 — intervention group
Group type: EXPERIMENTAL
Intervention: Amethocaine preparation vs EMLA
Number of subjects: 0
Study 53598 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly isoniazid 15 mg/kg plus rifampicin 900 mg (HR2 regimen)
Number of subjects: 481
Study 53598 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly isoniazid 15 mg/kg plus rifampicin 600 mg (LR2 regimen)
Number of subjects: 481
Study 53598 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly isoniazid 15 mg/kg plus rifampicin 900 mg (HR1 regimen)
Number of subjects: 481
Study 53598 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly isoniazid 15 mg/kg plus rifampicin 600 mg (LR1 regimen)
Number of subjects: 481
Study 53598 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 25 mg supplement
Number of subjects: 481
Study 31276986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced profile with graphical representation of prescriptions and identified risky prescribing patterns
Number of subjects: 50
Study 31276986 — intervention group
Group type: COMPARATOR
Intervention: Standard profile
Number of subjects: 50
Study 28832280 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination with a three‐dose hepatitis B vaccine
Number of subjects: 150
Study 28832280 — intervention group
Group type: COMPARATOR
Intervention: Deferred vaccination (at 12 months)
Number of subjects: 150
Study 28832280 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate vaccination group
Number of subjects: 150
Study 28832280 — intervention group
Group type: COMPARATOR
Intervention: Deferred vaccination group
Number of subjects: 150
Study 28832280 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of trial procedures and services
Number of subjects: 150
Study 28832280 — intervention group
Group type: EXPERIMENTAL
Intervention: Future trial participation motivation
Number of subjects: 150
Study 26117150 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered LAIV (SA)
Number of subjects: 1077
Study 26117150 — intervention group
Group type: COMPARATOR
Intervention: Healthcare worker-administered LAIV (HCWA)
Number of subjects: 1077
Study 26117150 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration (SA)
Number of subjects: 1077
Study 23612197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (200 mg/day)
Number of subjects: 0
Study 23612197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21713729 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristbands applied at the P6 points
Number of subjects: 200
Study 21713729 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 200
Study 21713729 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg/kg iv
Number of subjects: 200
Study 21713729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 200
Study 18850765 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 0
Study 18850765 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 16156391 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiac faecal blood testing
Number of subjects: 300000
Study 16156391 — intervention group
Group type: COMPARATOR
Intervention: Immunochemical testing
Number of subjects: 300000
Study 16156391 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of GPs based on personal skills
Number of subjects: 300000
Study 12173201 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 80
Study 12173201 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (LMA)
Number of subjects: 80
Study 10499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondistinctive image
Number of subjects: 100
Study 10499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft lip image
Number of subjects: 100
Study 10499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Misshapen nose image
Number of subjects: 100
Study 10499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 100
Study 10499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 100
Study 8522638 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg orally once daily for 6 days
Number of subjects: 12
Study 2185026 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (100 mg phospholipid/kg, 4 ml/kg)
Number of subjects: 106
Study 2185026 — intervention group
Group type: COMPARATOR
Intervention: Air (4 ml/kg)
Number of subjects: 106
Study 349091 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (500 mg every 8 hr for 7 days)
Number of subjects: 65
Study 349091 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (500 mg every 8 hr for 7 days)
Number of subjects: 65
Study 29555485 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronobiological treatment (light therapy) for Delayed Sleep-Wake Phase Disorder for 3 weeks
Number of subjects: 0
Study 29555485 — intervention group
Group type: COMPARATOR
Intervention: Good sleeping adolescents (control group)
Number of subjects: 0
Study 27230855 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d rasagiline
Number of subjects: 44
Study 27230855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25230559 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (10 mg per day for 12 weeks)
Number of subjects: 82
Study 25230559 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no antioxidants, drugs, vitamins or dietary supplements)
Number of subjects: 82
Study 23773316 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet recommendations for 6 weeks
Number of subjects: 60
Study 23773316 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice (UDA) for 6 weeks
Number of subjects: 60
Study 19394598 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 20 mg orally twice a day after LNG-SI insertion
Number of subjects: 40
Study 19394598 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally twice a day after LNG-SI insertion
Number of subjects: 40
Study 19394598 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 20 mg
Number of subjects: 40
Study 19394598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19007597 — intervention group
Group type: EXPERIMENTAL
Intervention: Impella LP2.5
Number of subjects: 26
Study 19007597 — intervention group
Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 26
Study 19007597 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 26
Study 16422827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 253
Study 16422827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 253
Study 16422827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 12868026 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox (50:50 N2O/O2)
Number of subjects: 100
Study 12868026 — intervention group
Group type: COMPARATOR
Intervention: Air (placebo)
Number of subjects: 100
Study 12868026 — intervention group
Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 100
Study 10877482 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing an elastic lumbar back support
Number of subjects: 0
Study 9437192 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 diet
Number of subjects: 26
Study 9437192 — intervention group
Group type: EXPERIMENTAL
Intervention: n-6 diet
Number of subjects: 26
Study 9437192 — intervention group
Group type: COMPARATOR
Intervention: saturated diet
Number of subjects: 26
Study 8475547 — intervention group
Group type: EXPERIMENTAL
Intervention: OG37-325
Number of subjects: 0
Study 8475547 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 3515928 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 26
Study 3515928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31203569 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using light-emitting diode (LED) irradiation at 150 J
Number of subjects: 11
Study 31203569 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) using light-emitting diode (LED) irradiation at 300 J
Number of subjects: 11
Study 31203569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no PBM)
Number of subjects: 11
Study 29258362 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative cognitive style
Number of subjects: 179
Study 29258362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response to laboratory stress induction
Number of subjects: 179
Study 26905354 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-lock technique (ALT) at the dorsogluteal site (DS)
Number of subjects: 60
Study 26905354 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-lock technique (ALT) at the ventrogluteal site (VS)
Number of subjects: 60
Study 26905354 — intervention group
Group type: COMPARATOR
Intervention: No air-lock technique at the dorsogluteal site (DS)
Number of subjects: 60
Study 26905354 — intervention group
Group type: COMPARATOR
Intervention: No air-lock technique at the ventrogluteal site (VS)
Number of subjects: 60
Study 25348157 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) protocol
Number of subjects: 0
Study 25348157 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 22873680 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg every 12 hours plus fluvoxamine
Number of subjects: 42
Study 22873680 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours plus fluvoxamine
Number of subjects: 42
Study 20033055 — intervention group
Group type: EXPERIMENTAL
Intervention: CD3(+)/CD19(+)-depleted PBSC grafts
Number of subjects: 0
Study 20033055 — intervention group
Group type: COMPARATOR
Intervention: CD34(+)-selected PBSC grafts
Number of subjects: 0
Study 18614889 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (group 1; 11 SSF) for 4 weeks
Number of subjects: 14
Study 18614889 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (group 2; 5 SSF) for 4 weeks
Number of subjects: 14
Study 16018911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of CAM RCTs
Number of subjects: 600
Study 16018911 — intervention group
Group type: COMPARATOR
Intervention: Reports of CM RCTs
Number of subjects: 600
Study 16018911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports in English for CAM trials
Number of subjects: 600
Study 16018911 — intervention group
Group type: COMPARATOR
Intervention: Reports in other languages for CAM trials
Number of subjects: 600
Study 16018911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports in English for CM trials
Number of subjects: 600
Study 16018911 — intervention group
Group type: COMPARATOR
Intervention: Reports in other languages for CM trials
Number of subjects: 600
Study 11980746 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with small intramural fibroids undergoing IVF
Number of subjects: 0
Study 11980746 — intervention group
Group type: COMPARATOR
Intervention: Control group (women without fibroids)
Number of subjects: 0
Study 10392939 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2)
Number of subjects: 35
Study 10392939 — intervention group
Group type: COMPARATOR
Intervention: Iodinated contrast material
Number of subjects: 35
Study 8945569 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunization
Number of subjects: 13
Study 8945569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal immunization
Number of subjects: 13
Study 1627428 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (XRT) with full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy; patients with positive axillary dissections also received cyclophosphamide and doxorubicin
Number of subjects: 237
Study 1627428 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 237
Study 6702864 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 29
Study 6702864 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 29
Study 30674240 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 450 mg daily (group 1)
Number of subjects: 196
Study 30674240 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 900 mg daily (group 2)
Number of subjects: 196
Study 27863065 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 117
Study 27863065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 26855980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage quetiapine (150 mg/d)
Number of subjects: 95
Study 26855980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dosage quetiapine (300 mg/d)
Number of subjects: 95
Study 26855980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 23016508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (90 mg gel once daily)
Number of subjects: 518
Study 23016508 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (250 mg weekly)
Number of subjects: 518
Study 23016508 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 518
Study 23016508 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone
Number of subjects: 518
Study 21708967 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary integrated care
Number of subjects: 340
Study 21708967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 19440086 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 30
Study 19440086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16631923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cycling (20,000 cycles under 50 N load, immersion in distilled water at 37 degrees C)
Number of subjects: 40
Study 16631923 — intervention group
Group type: COMPARATOR
Intervention: No mechanical cycling
Number of subjects: 40
Study 15609842 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 33
Study 15609842 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 33
Study 12036265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive two-stage dose-response trial
Number of subjects: 0
Study 12036265 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-function based approach for dose selection
Number of subjects: 0
Study 12036265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive two-stage designs with dose-selection rule
Number of subjects: 0
Study 10332319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 0